Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 2/2/2026

Avoidance of Invasive Ophthalmic Procedures in Vascular Ehlers‑Danlos Syndrome

Imaging Recommendations

  • Non‑invasive vascular imaging (e.g., Doppler ultrasound, MR angiography) is strongly preferred for patients with vascular EDS because invasive imaging has been linked to fatal hemorrhagic complications due to tissue fragility. 1
  • The same principle extends to ophthalmologic imaging; clinicians should avoid invasive ocular imaging modalities whenever possible in vascular EDS. 2

Surgical and Procedural Precautions

  • All intra‑ocular procedures (including cataract surgery, laser treatments, and diagnostic angiography) must be performed with extreme caution in vascular EDS because of heightened bleeding risk and tissue fragility. 4
  • Invasive procedures in vascular EDS patients should be minimized or replaced with conservative alternatives to reduce the risk of catastrophic hemorrhage. 3

Corneal Ectasia Risk

  • Ehlers‑Danlos syndrome is an established risk factor for postoperative corneal ectasia after refractive surgery; clinicians should consider this when evaluating candidates for laser vision correction. 4
  • The risk of corneal ectasia is further emphasized in recent ophthalmology literature, underscoring the need for thorough pre‑operative corneal assessment in EDS patients. 5

Dry‑Eye Disease Management

  • Management of dry‑eye disease in EDS should include preservative‑free artificial tears, mast‑cell stabilizers when atopic disease is present, and patient counseling to avoid eye rubbing. 5

Atopic Disease Considerations

  • Screening for co‑existing atopic conditions (e.g., allergic rhinitis, asthma, eczema) is recommended because these disorders can exacerbate eye rubbing and accelerate corneal pathology in EDS. 5

Genetic Confirmation of Vascular EDS

  • Definitive diagnosis of vascular EDS requires molecular testing that identifies pathogenic variants in the COL3A1 gene, using DNA sequencing or protein analysis. 1
  • European Heart Journal guidelines also endorse COL3A1 genetic testing as the gold standard for confirming vascular EDS. 6

REFERENCES